Veracyte VCYT Contract manufacturing and testing — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's contract manufacturing and testing — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's contract manufacturing and testing — total revenue?
- Veracyte (VCYT) reported contract manufacturing and testing — total revenue of $0 in Q1 2026.
- How has Veracyte's contract manufacturing and testing — total revenue changed year-over-year?
- Veracyte's contract manufacturing and testing — total revenue decreased by 100.0% year-over-year, from $1.29M to $0.
- What is the long-term trend for Veracyte's contract manufacturing and testing — total revenue?
- Over 4 years (2021 to 2025), Veracyte's contract manufacturing and testing — total revenue has grown at a -1.0% compound annual growth rate (CAGR), from $3.26M to $3.13M.
- What does contract manufacturing and testing — total revenue mean?
- This metric represents the total gross revenue generated from providing specialized contract manufacturing and laboratory testing services to biopharmaceutical partners. It reflects the company's ability to monetize its technical infrastructure and diagnostic capabilities through third-party service agreements. Tracking this revenue stream helps investors assess the contribution of non-core service activities to the overall business model and the stability of external partnership-driven income.